Guangzhou Baiyunshan Pharmaceutical Holdings Company (HK:0874) has released an update.
Guangzhou Baiyunshan Pharmaceutical Holdings Company has announced that its subsidiary, Guangxi Baiyunshan Yingkang Pharmaceutical Co., Ltd., has received approval for a supplemental drug application from the National Medical Products Administration. The approval pertains to a change in the subject of the drug marketing authorization for their product, Compound Paracetamol and Pseudoephedrine Granules. This regulatory milestone is an important step for the company’s product portfolio.
For further insights into HK:0874 stock, check out TipRanks’ Stock Analysis page.
